









Markets
/
Stocks
/
nasdaq-athe
/

Alterity Therapeutics Ltd

ATHE

View Detailed Chart

5.240USD

+0.230+4.59%

Market hours （ET）Quotes delayed by 15 min

46.46MMarket Cap

--P/E TTM



Alterity Therapeutics Ltd

5.240

+0.230+4.59%

Overview Company Financials

Financials

Intraday

30m

Today

+4.59%

5 Days

-20.00%

1 Month

+26.27%

6 Months

+5.01%

Year to Date

+58.31%

1 Year

+274.29%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 2 analysts

STRONG BUY

Current Rating

11.000

Target Price

119.56%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

552

Total

Median

Average

Company name

Ratings

Analysts

Alterity Therapeutics Ltd

ATHE

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Ionis Pharmaceuticals Inc

IONS

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Neutral

Sell(4)

Neutral(3)

Buy(5)

Indicators

Sell(3)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.010

Neutral

RSI(14)

52.202

Neutral

STOCH(KDJ)(9,3,3)

14.251

Sell

ATR(14)

0.571

High Vlolatility

CCI(14)

-31.124

Neutral

Williams %R

74.532

Sell

TRIX(12,20)

1.167

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

5.232

Buy

MA10

5.344

Sell

MA20

4.858

Buy

MA50

4.562

Buy

MA100

4.084

Buy

MA200

3.283

Buy

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.

Ticker SymbolATHE

CompanyAlterity Therapeutics Ltd

CEODr. David A. Stamler, M.D.

Websitehttps://alteritytherapeutics.com/